Not sure where to start? Try searching for your diagnosis above or visit the "Conditions" section.
4 items
A landmark phase 3 trial found that obinutuzumab, a targeted anti-CD20 antibody, significantly outperformed placebo in reducing disease acti...
View — Obinutuzumab Achieves Superior Disease Control in Phase 3 ALLEGORY Trial for Systemic Lupus Erythematosus »A longitudinal study from the Lupus Clinic at Sapienza University of Rome followed 201 patients with undifferentiated connective tissue dise...
View — Longitudinal Study Reveals Which UCTD Patients Are Most Likely to Evolve to Lupus Under Updated 2019 Classification Criteria »Sirolimus, a decades-old transplant drug, just delivered the first rigorous, placebo-controlled proof that blocking a pathway called mTOR ca...
View — A 125-Year-Old Drug Gets Its First Real Lupus Trial »Aurinia Pharmaceuticals has launched a new study testing whether pairing its approved lupus nephritis drug with one of three newer biologics...
View — A Combination Approach to the Toughest Lupus Kidney Cases »